Megarounds for Chinese biopharmas Legend, RemeGen to support late-stage push

A pair of Chinese biotechs raised rounds topping $100 million this week, with Legend’s fund-raise coming ahead of a planned U.S. IPO and regulatory submissions for its lead CAR T targeting BCMA, and cancer and autoimmune company RemeGen adding at least four new investors to its syndicate.

Legend Biotech Co.’s $150.5 million series

Read the full 528 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE